Company Overview and News
Stop missing out on important events!
Biotron’s (ASX:BIT) shares were trading 5.5% higher intra-day after completing patient recruitment for the phase 2 HIV-1 clinical trial of its lead antiviral drug, BIT225.
Biotron (ASX:BIT) has commenced the Phase 2 human clinical trial of its lead antiviral drug BIT225 in patients with Human Immunodeficiency Virus (HIV-1) infection.
NEW YORK, March 17, 2016 /PRNewswire/ -- Biotron Limited (ASX: BIT) confirms positive outcomes from its Phase 2 study of its first-in-class antiviral drug BIT225.